Archive for the ‘Crohn’s disease’ tag
Humira for Rheumatoid Arthritis
Click on image to view ad details and full-size version on AdPharm.
To see all of this brand’s ads on AdPharm, click here
Remicade – Check the facts
Click on image to view ad details and full-size version on AdPharm
To see all of this brand’s ads on AdPharm, click here
Humira
In moderate to severe Crohn’s disease, demonstrated to sustain power, sustain remission.
Adalimumab (brand name HUMIRA) is the third TNF inhibitor, after infliximab and etanercept, to be approved in the United States. Like infliximab and etanercept, adalimumab binds to TNFa, preventing it from activating TNF receptors; adalimumab was constructed from a fully human monoclonal antibody, while infliximab is a mouse-human chimeric antibody and etanercept is a TNF receptor-IgG fusion protein. TNFa inactivation has proven to be important in downregulating the inflammatory reactions associated with autoimmune diseases. As of 2008 adalimumab has been approved by the FDA for the treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, moderate to severe chronic psoriasis and juvenile idiopathic arthritis.
Humira (brand name is an abbreviation of "Human Monoclonal Antibody in Rheumatoid Arthritis") is marketed in both preloaded 0.8 ml syringes and also in preloaded pen devices (called Humira Pen), both injected subcutaneously, typically by the patient at home. It cannot be administered orally, because the digestive system would destroy the drug.
Humira’s manufacturer is Abbott Laboratories. – Wikipedia
CMAJ April 2009
More Humira ads on AdPharm
